DongKook Pharmaceutical is forecast to grow earnings and revenue by 15.9% and 11.6% per annum respectively. EPS is expected to grow by 15.5% per annum. Return on equity is forecast to be 13.2% in 3 years.
KOSDAQ:A086450 - Analysts future estimates and past financials data (KRW Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
12/31/2028
1,317,900
118,800
N/A
130,200
1
12/31/2027
1,177,700
104,600
N/A
115,100
1
12/31/2026
1,052,000
92,500
N/A
113,700
1
3/31/2026
954,164
74,518
27,006
80,512
N/A
12/31/2025
926,884
66,020
22,964
68,760
N/A
9/30/2025
894,935
60,553
38,272
75,787
N/A
6/30/2025
869,004
59,849
44,439
78,839
N/A
3/31/2025
839,081
57,649
43,683
71,765
N/A
12/31/2024
812,166
60,769
44,862
76,091
N/A
9/30/2024
789,114
61,237
21,358
57,081
N/A
6/30/2024
764,673
54,080
4,190
44,313
N/A
3/31/2024
747,013
50,413
5,645
43,834
N/A
12/31/2023
730,994
46,775
2,203
41,793
N/A
9/30/2023
709,543
47,176
-4,834
38,961
N/A
6/30/2023
692,794
46,959
6,550
41,667
N/A
3/31/2023
676,772
53,131
7,390
43,763
N/A
12/31/2022
661,647
52,896
-11,064
40,909
N/A
9/30/2022
645,744
58,943
-2,673
45,738
N/A
6/30/2022
631,065
55,611
-12,494
48,082
N/A
3/31/2022
615,974
50,919
-16,170
49,477
N/A
12/31/2021
594,193
50,345
-5,022
44,654
N/A
9/30/2021
585,740
43,945
1,639
47,422
N/A
6/30/2021
588,360
52,484
25,343
60,698
N/A
3/31/2021
572,391
54,515
5,616
48,930
N/A
12/31/2020
559,103
55,925
17,814
59,108
N/A
9/30/2020
544,685
63,502
19,859
65,202
N/A
6/30/2020
520,469
61,569
13,244
59,474
N/A
3/31/2020
502,390
60,360
38,679
68,633
N/A
12/31/2019
482,280
56,312
N/A
69,483
N/A
9/30/2019
456,230
53,797
N/A
60,123
N/A
6/30/2019
436,293
50,618
N/A
49,945
N/A
3/31/2019
418,583
49,157
N/A
32,790
N/A
12/31/2018
400,807
46,949
N/A
33,209
N/A
9/30/2018
391,801
45,695
N/A
30,618
N/A
6/30/2018
378,388
42,872
N/A
36,546
N/A
3/31/2018
366,905
41,695
N/A
41,149
N/A
12/31/2017
354,768
39,602
N/A
28,659
N/A
9/30/2017
342,293
38,070
N/A
28,869
N/A
6/30/2017
330,629
39,996
N/A
28,465
N/A
3/31/2017
320,349
40,421
N/A
34,431
N/A
12/31/2016
309,690
40,660
N/A
39,412
N/A
9/30/2016
302,007
38,101
N/A
42,036
N/A
6/30/2016
292,760
35,192
N/A
40,984
N/A
3/31/2016
275,174
30,488
N/A
36,877
N/A
12/31/2015
259,930
27,426
N/A
27,143
N/A
9/30/2015
244,766
23,139
N/A
20,752
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: A086450's forecast earnings growth (15.9% per year) is above the savings rate (3.1%).
Earnings vs Market: A086450's earnings (15.9% per year) are forecast to grow slower than the KR market (27.3% per year).
High Growth Earnings: A086450's earnings are forecast to grow, but not significantly.
Revenue vs Market: A086450's revenue (11.6% per year) is forecast to grow slower than the KR market (14.7% per year).
High Growth Revenue: A086450's revenue (11.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: A086450's Return on Equity is forecast to be low in 3 years time (13.2%).
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/08/03 13:39
End of Day Share Price
2026/08/03 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DongKook Pharmaceutical Co., Ltd. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.